The European Medicines Agency (EMA) accepted Bristol-Myers Squibb's $BMY type II variation application looking for approval of the use of Opdivo (nivolumab) for the treatment of locally advanced unresectable or metastatic urothelial carcinoma in adults who fail to respond to prior platinum-based therapy. Opdivo is currently approved in the EU for the treatment of melanoma, non-small cell lung cancer and renal cell carcinoma, which is a kidney cancer.